Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...
NCCN guidelines are evidence-informed, consensus-driven, and influential in US payer policies, with a focus on multidisciplinary representation and global adaptations. ESMO guidelines reduce care ...
“Lung cancer, though common and serious, still has many misconceptions,” says Ian Bostock, MD, a thoracic surgeon at Miami Cancer Institute in Florida. “Clearing these myths helps patients and ...
What Is Hyrnuo, and Why Does It Matter? Hyrnuo (sevabertinib) is a new oral medicine for adults with advanced nonsquamous non-small-cell lung cancer (NSCLC) carrying a specific genetic change known as ...
Alecensa reduced death risk by 22% compared to Xalkori in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. The study was not powered for OS, resulting in ...
For stage 4 lung cancer treatment to be effective, it is essential that doctors perform accurate diagnosis before any therapy begins. They must determine the cancer's location and spread, as well as ...
This fact sheet explains how lung cancer is staged, and what each stage means. Lung cancer staging can be complex, but this fact sheet is intended for patient education. Our easy-to-read fact sheets ...
CHICAGO - Lung cancer is responsible for approximately 1 in 4 cancer deaths in the United States, making it the deadliest ...
In his 20-year research career in Colorado, University of Colorado Cancer Center member D. Ross Camidge, MD, PhD, has published nearly 400 academic papers. But perhaps none have been so personal to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback